A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 09 Feb 2012 New trial record